KEGG   DRUG: Cerliponase alfaHelp
Entry
D10813                      Drug                                   

Name
Cerliponase alfa (USAN/INN);
Cerliponase alfa (genetical recombination) (JAN)
Product
Sequence
SYSPEPDQRR TLPPGWVSLG RADPEEELSL TFALRQQNVE RLSELVQAVS DPSSPQYGKY
LTLENVADLV RPSPLTLHTV QKWLLAAGAQ KCHSVITQDF LTCWLSIRQA ELLLPGAEFH
HYVGGPTETH VVRSPHPYQL PQALAPHVDF VGGLHRFPPT SSLRQRPEPQ VTGTVGLHLG
VTPSVIRKRY NLTSQDVGSG TSNNSQACAQ FLEQYFHDSD LAQFMRLFGG NFAHQASVAR
VVGQQGRGRA GIEASLDVQY LMSAGANIST WVYSSPGRHE GQEPFLQWLM LLSNESALPH
VHTVSYGDDE DSLSSAYIQR VNTELMKAAA RGLTLLFASG DSGAGCWSVS GRHQFRPTFP
ASSPYVTTVG GTSFQEPFLI TNEIVDYISG GGFSNVFPRP SYQEEAVTKF LSSSPHLPPS
SYFNASGRAY PDVAALSDGY WVVSNRVPIP WVSGTSASTP VFGGILSLIN EHRILSGRPP
LGFLNPRLYQ QHGAGLFDVT RGCHESCLDE EVEGQGFCSG PGWDPVTGWG TPNFPALLKT
LLNP
(disulfide bridges: 92-103, 346-507, 503-518)
  Type
Peptide
Remark
ATC code: A16AB17
Product: D10813<US>
Efficacy
Replenisher (tripeptidyl peptidase 1)
  Disease
Neuronal ceroid lipofuscinosis type 2 [DS:H00149]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
    A16AB Enzymes
     A16AB17 Cerliponase alfa
      D10813  Cerliponase alfa (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10813
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10813
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10813
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and germline mutations
  D10813
BRITE hierarchy
Other DBs
CAS: 151662-36-1
PubChem: 319902614
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system